StreetInsider.com News Articles

ImmunityBio completes NK cell manufacturing programs with 74 subjects

Fri, 13 Mar 2026 07:30:44 -0400

ImmunityBio (NASDAQ: IBRX) announced completion of manufacturing programs establishing a pathway for its autologous memory cytokine-enhanced natural killer cell therapy platform. The company enrolled 74 subjects across programs NK2022, NK2023, and a Phase 1 safety trial.

The programs demonstrated that single apheresis procedures can yield up to 5 billion NK cells, providing 8-10 therapeutic doses per patient with finished products available within 12 days. Among 64 subjects who completed apheresis collection, no procedure-related serious adverse events occurred.

In the Phase 1 trial QUILT-3.076, 10 cancer patients received M-ceNK cell infusions combined with ANKTIVA in an outpatient setting. The trial included patients with

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Fri, 13 Mar 2026 07:30:00 -0400

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis
M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines
Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)
Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076)

BTIG Assumes Immunitybio Inc (IBRX) at Buy

Wed, 11 Mar 2026 16:11:11 -0400

(Updated - March 11, 2026 4:11 PM EDT)

BTIG analyst Jeet Mukherjee assumes coverage on Immunitybio Inc (NASDAQ: IBRX) with a Buy rating and a price target of $13.00.

The analyst comments "IBRX has had a strong start to 2026, with the stock up 318% YTD driven by 700% y/y growth for ANKTIVA in the US, EU conditional marketing approval, and approval for NSCLC in Saudi Arabia. We believe further share appreciation from here will be led by continued ANKTIVA commercial execution and label expansion. On the clinical/regulatory front, IBRX is targeting a YE26 BLA submission for BCG-naïve cis NMIBC based on

BTIG Assumes Immunitybio Inc (IBRX) at Buy

Wed, 11 Mar 2026 16:11:11 -0400

(Updated - March 11, 2026 4:11 PM EDT)

BTIG analyst Jeet Mukherjee assumes coverage on Immunitybio Inc (NASDAQ: IBRX) with a Buy rating and a price target of $13.00.

ImmunityBio resubmits cancer treatment application to FDA

Mon, 09 Mar 2026 07:31:27 -0400

ImmunityBio (NASDAQ: IBRX) has resubmitted a supplemental biologics license application to the U.S. Food and Drug Administration for its ANKTIVA treatment combined with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer containing papillary tumors.

The FDA acknowledged receipt of the resubmitted filing after reviewing additional data provided by the company in February 2026. The resubmission followed ongoing discussions with the FDA beginning in January 2026, during which the agency requested additional information to support its review without requiring new clinical trials.

The application is supported by long-term results from the QUILT 3.032 Phase 2/3 trial involving 80 patients with high-grade papillary-only

ImmunityBio resubmits cancer treatment application to FDA

Mon, 09 Mar 2026 07:31:27 -0400

The application is supported by long-term results from the QUILT 3.032 Phase 2/3 trial involving 80 patients with high-grade papillary-only

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data